GB201811382D0 - Vaccine - Google Patents

Vaccine

Info

Publication number
GB201811382D0
GB201811382D0 GBGB1811382.9A GB201811382A GB201811382D0 GB 201811382 D0 GB201811382 D0 GB 201811382D0 GB 201811382 A GB201811382 A GB 201811382A GB 201811382 D0 GB201811382 D0 GB 201811382D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1811382.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HAV Vaccines Ltd
Original Assignee
TAYLOR JOHN HERMON
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAYLOR JOHN HERMON filed Critical TAYLOR JOHN HERMON
Priority to GBGB1811382.9A priority Critical patent/GB201811382D0/en
Publication of GB201811382D0 publication Critical patent/GB201811382D0/en
Priority to IL280070A priority patent/IL280070B2/en
Priority to BR112021000312-6A priority patent/BR112021000312A2/pt
Priority to AU2019301899A priority patent/AU2019301899A1/en
Priority to US17/259,075 priority patent/US12186382B2/en
Priority to SG11202100120TA priority patent/SG11202100120TA/en
Priority to EP19752222.0A priority patent/EP3820507A1/en
Priority to PCT/GB2019/051933 priority patent/WO2020012177A1/en
Priority to CN201980059761.5A priority patent/CN113329765A/zh
Priority to MA053131A priority patent/MA53131A/fr
Priority to CA3105763A priority patent/CA3105763A1/en
Priority to MX2020013924A priority patent/MX2020013924A/es
Priority to KR1020217004231A priority patent/KR20210033490A/ko
Priority to JP2021500530A priority patent/JP2021524485A/ja
Priority to JP2024109065A priority patent/JP2024153666A/ja
Priority to US18/954,032 priority patent/US20250152691A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1811382.9A 2018-07-11 2018-07-11 Vaccine Ceased GB201811382D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB1811382.9A GB201811382D0 (en) 2018-07-11 2018-07-11 Vaccine
JP2021500530A JP2021524485A (ja) 2018-07-11 2019-07-10 パラ結核症のための免疫原性組成物
EP19752222.0A EP3820507A1 (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis
CN201980059761.5A CN113329765A (zh) 2018-07-11 2019-07-10 用于副结核病的免疫原性组合物
AU2019301899A AU2019301899A1 (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis
US17/259,075 US12186382B2 (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis
SG11202100120TA SG11202100120TA (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis
IL280070A IL280070B2 (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis
PCT/GB2019/051933 WO2020012177A1 (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis
BR112021000312-6A BR112021000312A2 (pt) 2018-07-11 2019-07-10 Vacina, peptídeos, polipeptídeo, polinucleotídeo, vetor de vacina, método de tratamento ou prevenção da infecção por map ou da condição ou sintoma associado à infecção por map e kit
MA053131A MA53131A (fr) 2018-07-11 2019-07-10 Composition immunogène pour la paratuberculose
CA3105763A CA3105763A1 (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis
MX2020013924A MX2020013924A (es) 2018-07-11 2019-07-10 Composicion inmunogena para paratuberculosis.
KR1020217004231A KR20210033490A (ko) 2018-07-11 2019-07-10 파라튜버큘로시스에 대한 면역원성 조성물
JP2024109065A JP2024153666A (ja) 2018-07-11 2024-07-05 パラ結核症のための免疫原性組成物
US18/954,032 US20250152691A1 (en) 2018-07-11 2024-11-20 Immunogenic composition for paratuberculosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1811382.9A GB201811382D0 (en) 2018-07-11 2018-07-11 Vaccine

Publications (1)

Publication Number Publication Date
GB201811382D0 true GB201811382D0 (en) 2018-08-29

Family

ID=63273113

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1811382.9A Ceased GB201811382D0 (en) 2018-07-11 2018-07-11 Vaccine

Country Status (14)

Country Link
US (2) US12186382B2 (enExample)
EP (1) EP3820507A1 (enExample)
JP (2) JP2021524485A (enExample)
KR (1) KR20210033490A (enExample)
CN (1) CN113329765A (enExample)
AU (1) AU2019301899A1 (enExample)
BR (1) BR112021000312A2 (enExample)
CA (1) CA3105763A1 (enExample)
GB (1) GB201811382D0 (enExample)
IL (1) IL280070B2 (enExample)
MA (1) MA53131A (enExample)
MX (1) MX2020013924A (enExample)
SG (1) SG11202100120TA (enExample)
WO (1) WO2020012177A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
WO2026041756A1 (en) 2024-08-21 2026-02-26 Hav Vaccines Limited Treatment of crohn's disease by mycobacterium avium subsp. paratuberculosis agent

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5225324A (en) 1987-04-24 1993-07-06 Bioscience International, Inc. Diagnostics for mycobacteria in public health, medical, and veterinary practice
GB8709803D0 (en) 1987-04-24 1987-05-28 Mcfadden J J Treatment of crohn's disease &c
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JPH07505283A (ja) 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン Ｄｎａトランスポーター系および使用方法
AU682308C (en) 1992-04-03 2006-08-17 Regents Of The University Of California, The Self-assembling polynucleotide delivery system
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
GB9526178D0 (en) 1995-12-21 1996-02-21 Taylor John Hermon Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
ATE466876T1 (de) 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogene konstrukte
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
EP2710151A4 (en) 2011-05-19 2014-12-10 Univ Central Florida Res Found MICROBEND DETECTION BY HYBRIDIZATION OF MAGNETIC RELAXATION NANOSENSORS
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
JP2016513078A (ja) * 2013-01-28 2016-05-12 ダンマルクス テクニスケ ウニベルシテット 一段階または多段階のトリ型結核菌亜種副結核症サブユニット・ワクチン
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic

Also Published As

Publication number Publication date
US20210338791A1 (en) 2021-11-04
IL280070A (en) 2021-03-01
JP2021524485A (ja) 2021-09-13
IL280070B1 (en) 2023-12-01
US20250152691A1 (en) 2025-05-15
IL280070B2 (en) 2024-04-01
MX2020013924A (es) 2021-03-02
CN113329765A (zh) 2021-08-31
CA3105763A1 (en) 2020-01-16
KR20210033490A (ko) 2021-03-26
MA53131A (fr) 2021-05-19
SG11202100120TA (en) 2021-02-25
JP2024153666A (ja) 2024-10-29
EP3820507A1 (en) 2021-05-19
WO2020012177A1 (en) 2020-01-16
AU2019301899A1 (en) 2021-01-14
BR112021000312A2 (pt) 2021-04-13
US12186382B2 (en) 2025-01-07

Similar Documents

Publication Publication Date Title
DK3467457T3 (en) Vibrationssensor
CA185383S (en) Casque
CA185384S (en) Casque
CA185382S (en) Casque
SG11202010821TA (en) Vaccine composition
CA185385S (en) Casque
DK3554057T3 (en) Audioheadsetsystem
CA184994S (en) Uroflowmeter
GB2575859B (en) Ice-lined vaccine refrigerator
GB201802375D0 (en) Retaining members
CA184989S (en) Uroflowmeter
SG11202009147UA (en) Vaccine compositions
GB201608821D0 (en) Vaccines
GB201910794D0 (en) Vaccine
GB201616904D0 (en) Vaccine
DK3768906T3 (en) Træmodul
GB201703529D0 (en) Vaccine composition
GB201911636D0 (en) Vaccine
GB201807303D0 (en) Glyconjugate vaccines
DK3570498T3 (en) Adaptivt hvac-styresystem
GB201603029D0 (en) Vaccine
CA187782S (en) Pompon-maker
DK3542617T3 (en) Etikette
GB201712904D0 (en) Vaccine
GB201807376D0 (en) HMCV Vaccine Composition

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: HAV VACCINES LIMITED

Free format text: FORMER OWNER: JOHN HERMON-TAYLOR

AT Applications terminated before publication under section 16(1)